Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2

Status

Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 4Endocrine 4Thoracic 3NET 2Lymphoid 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Sarcoma 3Osteosarcoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × surufatinib × Sarcoma × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
130 enrolled 30 charts
EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive

NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT05590572 2022-10-21

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
148 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡